Newland Pharmaceutical Co., Ltd.

1. Moxifloxacin hydrochloride tablets (specification: 0.4 g) from Xintiandi Pharmaceutical Co., Ltd. as the test preparation and moxifloxacin hydrochloride tablets (specification: 0.4 g, trade name: Baifule®) from Bayer Vital GmbH as the reference preparation were used to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-preparation, two-period crossover design. 2. Observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

1. The vildagliptin tablets (specification: 50 mg) certified by Henan Xintiandi Pharmaceutical Co., Ltd. were used as the test preparation T, and the vildagliptin tablets (specification: 50 mg, trade name: Galvus®) certified by Novartis Europharm Ltd. were used as the reference preparation R. The pharmacokinetic parameters of the test preparation and the reference preparation were compared, and the bioequivalence of the two preparations in the fasting and postprandial states was evaluated respectively. 2. Observe the safety of the test preparation vildagliptin tablets T and the reference preparation vildagliptin tablets R (trade name: Galvus®) in healthy subjects.